245 related articles for article (PubMed ID: 2455518)
1. Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets.
Simpson AW; Reeves ML; Rink TJ
Biochem Pharmacol; 1988 Jun; 37(12):2315-20. PubMed ID: 2455518
[TBL] [Abstract][Full Text] [Related]
2. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors.
Reeves ML; Leigh BK; England PJ
Biochem J; 1987 Jan; 241(2):535-41. PubMed ID: 3036066
[TBL] [Abstract][Full Text] [Related]
3. The effects of siguazodan, a selective phosphodiesterase inhibitor, on human platelet function.
Murray KJ; England PJ; Hallam TJ; Maguire J; Moores K; Reeves ML; Simpson AW; Rink TJ
Br J Pharmacol; 1990 Mar; 99(3):612-6. PubMed ID: 2158847
[TBL] [Abstract][Full Text] [Related]
4. Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors.
Komas N; Lugnier C; Stoclet JC
Br J Pharmacol; 1991 Oct; 104(2):495-503. PubMed ID: 1665741
[TBL] [Abstract][Full Text] [Related]
5. Incomplete reversal of beta-adrenoceptor desensitization in human and guinea-pig cardiomyocytes by cyclic nucleotide phosphodiesterase inhibitors.
Wynne DG; Poole-Wilson PA; Harding SE
Br J Pharmacol; 1993 Aug; 109(4):1071-8. PubMed ID: 7691363
[TBL] [Abstract][Full Text] [Related]
6. Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity.
Shafiee-Nick R; Pyne NJ; Furman BL
Br J Pharmacol; 1995 Aug; 115(8):1486-92. PubMed ID: 8564209
[TBL] [Abstract][Full Text] [Related]
7. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells.
Souness JE; Diocee BK; Martin W; Moodie SA
Biochem J; 1990 Feb; 266(1):127-32. PubMed ID: 2155604
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta.
Lugnier C; Schoeffter P; Le Bec A; Strouthou E; Stoclet JC
Biochem Pharmacol; 1986 May; 35(10):1743-51. PubMed ID: 2423089
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors.
Souness JE; Hassall GA; Parrott DP
Biochem Pharmacol; 1992 Sep; 44(5):857-66. PubMed ID: 1326964
[TBL] [Abstract][Full Text] [Related]
10. The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea-pig peritoneal macrophages.
Turner NC; Wood LJ; Burns FM; Gueremy T; Souness JE
Br J Pharmacol; 1993 Apr; 108(4):876-83. PubMed ID: 8387385
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities.
Nagakura N; Saeki T; Harada K; Yoshitake S; Kobayashi S; Yamanaka T; Saito I
Biol Pharm Bull; 1996 Jun; 19(6):828-33. PubMed ID: 8799481
[TBL] [Abstract][Full Text] [Related]
12. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
Eckly AE; Lugnier C
Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
[TBL] [Abstract][Full Text] [Related]
13. The effect of SK&F 95654, a novel phosphodiesterase inhibitor, on cardiovascular, respiratory and platelet function.
Murray KJ; Eden RJ; Dolan JS; Grimsditch DC; Stutchbury CA; Patel B; Knowles A; Worby A; Lynham JA; Coates WJ
Br J Pharmacol; 1992 Oct; 107(2):463-70. PubMed ID: 1422592
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors.
Dent G; Giembycz MA; Rabe KF; Barnes PJ
Br J Pharmacol; 1991 Jun; 103(2):1339-46. PubMed ID: 1653070
[TBL] [Abstract][Full Text] [Related]
15. The presence of five cyclic nucleotide phosphodiesterase isoenzyme activities in bovine tracheal smooth muscle and the functional effects of selective inhibitors.
Shahid M; van Amsterdam RG; de Boer J; ten Berge RE; Nicholson CD; Zaagsma J
Br J Pharmacol; 1991 Oct; 104(2):471-7. PubMed ID: 1665737
[TBL] [Abstract][Full Text] [Related]
16. Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form.
Lavan BE; Lakey T; Houslay MD
Biochem Pharmacol; 1989 Nov; 38(22):4123-36. PubMed ID: 2480793
[TBL] [Abstract][Full Text] [Related]
17. Benzodiazepines inhibit human platelet activation: comparison of the mechanism of antiplatelet actions of flurazepam and diazepam.
Romstedt K; Huzoor-Akbar
Thromb Res; 1985 May; 38(4):361-74. PubMed ID: 2990062
[TBL] [Abstract][Full Text] [Related]
18. Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis.
Torphy TJ; Zhou HL; Burman M; Huang LB
Mol Pharmacol; 1991 Mar; 39(3):376-84. PubMed ID: 1848659
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization.
Rabe KF; Tenor H; Dent G; Schudt C; Liebig S; Magnussen H
Am J Physiol; 1993 May; 264(5 Pt 1):L458-64. PubMed ID: 7684572
[TBL] [Abstract][Full Text] [Related]
20. The ability of denbufylline to inhibit cyclic nucleotide phosphodiesterase and its affinity for adenosine receptors and the adenosine re-uptake site.
Nicholson CD; Jackman SA; Wilke R
Br J Pharmacol; 1989 Jul; 97(3):889-97. PubMed ID: 2474352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
